Edwards Lifesciences Reports Third Quarter Results
Business Wire•04/11/2026•16:15 ET
0
Key Highlights
- ➤Q3 sales $1.72 billion, up 10.5% year over year
- ➤Adjusted EPS $0.80, up 19% versus prior year
- ➤TMTT sales $207 million, up 44.0% year over year
- ➤2026 sales growth guidance raised to approximately 11.5%
- ➤2026 adjusted EPS guidance raised to $2.97 to $3.05
Expert Statements
Bernard Zovighian, CEO of Edwards Lifesciences
“We delivered strong third-quarter growth of 11.2% which exceeded expectations, with broad-based performance across our businesses and regions, giving us the confidence to raise our full-year outlook.”
Bernard Zovighian, CEO of Edwards Lifesciences
“Our focused structural heart strategy, coupled with disciplined execution, long-term investments in category-creating innovation, and commitment to science and technology advancements, enabled us to deliver significant progress for patients on several of our most important clinical, regulatory, policy and commercial priorities this quarter.”
Bernard Zovighian, CEO of Edwards Lifesciences
“As I reflect on 2026 so far, I am proud of what our teams have accomplished and how we are positioning Edwards for strong, sustainable growth over the long term.”
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2026.
Q3 sales grew 10.5% to $1.72 billion(1), constant currency(2) sales grew 11.2%
Get started
Create a free account to read the full story.